Endpoint Ventures

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ (Click Activated Protodrugs Against Cancer) platform. The technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two ‘click’, a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds. We have already proven that our platform works in humans, which opens up an array of future possibilities for click-chemistry based therapies.

Viosera Therapeutics is a predict and block drug resistance in cancer and bacteria. The company discovers synergies between approved drugs and develop combinations of drugs that suppress resistance. Antibiotic resistance makes it necessary to develop better treatments for deadly infections. Viosera Therapeutics was founded in July 2016 and is headquartered in Sunnyvale, California.

FidoCure is transforming canine cancer care through AI-driven precision medicine. By harnessing data from naturally occurring canine cancers via next-generation sequencing and clinical information, FidoCure has developed the world's largest proprietary learning database for canine cancer. FidoCure is pioneering first-in-class care for canine cancer, which represents the largest unmet need for pet dogs. By connecting human and veterinary oncology, FidoCure enhances comparative oncology, improves outcomes across species, and creates new opportunities for drug development that benefit both pets and humans.

Synkrino Biotherapeutics is a biotech platform that discovers and develops novel drug targets directly from the immune system of patients. The platform is providing monitoring for pediatric rheumatologists for life-threatening conditions. It is currently building a rapid, portable field test for the RNA virus 2019-nCoV/COVID-19, adapting its existing analytic protocols for community public health screening. Synkrino Biotherapeutics' therapeutics use AI + Immunology Discovery Engine (AIDE Engine) which applies neural networks and machine learning to measure the immune tissue from patients to repeatably discover novel and biologically-valid drug targets, enabling healthcare providers to cure their patients and improve their lives.

Meru Health offers a digital program that helps improve the lives of people living with depression and saves on healthcare costs. It develops and delivers cost-effective, clinically proven, and engaging digital solutions to empower people living with depression. Founded by Kristian Ranta, Albert Nazander, and Riku Lindholm in 2015, Meru Health is headquartered in San Mateo, California.

HelpWear is striving to achieve better at-home healthcare by developing affordable and accessible products for patients all around the world. HelpWear’s focus is clinical need driven innovation, designing solutions to not only what a patient would need, but from a clinical perspective, to what the healthcare system requires as well.

BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.

BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.